Despite significant advancements in the development of novel therapies, cancer continues to stand as a prominent global cause of death. In many cases, the cornerstone of standard-of-care therapy consists of chemotherapy (CT), radiotherapy (RT), or a combination of both. Notably, hyperthermia (HT), which has been in clinical use in the last four decades, has proven to enhance the effectiveness of CT and RT, owing to its recognized potency as a sensitizer. Furthermore, HT exerts effects on all steps of the cancer–immunity cycle and exerts a significant impact on key oncogenic pathways. Most recently, there has been a noticeable expansion of cancer research related to treatment options involving immunotherapy (IT) and targeted therapy (TT), a trend also visible in the research and development pipelines of pharmaceutical companies. However, the potential results arising from the combination of these innovative therapeutic approaches with HT remain largely unexplored. Therefore, this review aims to explore the oncology pipelines of major pharmaceutical companies, with the primary objective of identifying the principal targets of forthcoming therapies that have the potential to be advantageous for patients by specifically targeting molecular pathways involved in HT. The ultimate goal of this review is to pave the way for future research initiatives and clinical trials that harness the synergy between emerging IT and TT medications when used in conjunction with HT.
尽管新型疗法的发展取得了显著进步，癌症依然是全球范围内主要的致死原因。在许多情况下，标准治疗方案的核心仍以化疗、放疗或两者联合为主。值得注意的是，热疗作为一种已在临床应用四十年的治疗手段，因其明确的增敏作用被证实能够增强化疗和放疗的疗效。此外，热疗能够影响癌症-免疫循环的所有环节，并对关键致癌通路产生显著影响。近年来，涉及免疫疗法和靶向治疗的癌症研究明显扩展，这一趋势在制药企业的研发管线中也日益凸显。然而，这些创新疗法与热疗联合应用的潜在效果仍亟待探索。因此，本综述旨在梳理主要制药企业的肿瘤研发管线，重点识别未来疗法的主要作用靶点——这些靶点通过特异性作用于热疗相关的分子通路，可能为患者带来临床获益。本综述的最终目标是为未来研究及临床试验指明方向，推动新兴免疫疗法和靶向治疗药物与热疗的协同应用。
肿瘤(癌症)患者之家